NeuroOne Medical Technologies Corporation announced its participation in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference, where company leadership will provide updates on commercialization efforts and pipeline milestones. The virtual presentation, scheduled for March 17, 2026, represents a significant opportunity for the medical technology company to communicate its progress to institutional investors and the broader healthcare community. President and CEO Dave Rosa and CFO Ron McClurg will host one-on-one meetings with institutional investors during the conference, with Rosa delivering a formal company presentation at 1:20 p.m. Eastern Time.
The presentation will focus specifically on commercialization updates and pipeline milestones for the OneRF platform, which is designed for treatment of the brain, pain management, and advanced drug delivery applications. This platform represents NeuroOne's core technology approach to transforming surgical diagnosis and treatment of neurological disorders. The company's participation in this prominent industry conference comes as NeuroOne continues to advance its FDA-cleared product families, including the Evo Cortical Electrodes, Evo sEEG Electrodes, OneRF Ablation System for brain applications, and OneRF Trigeminal Nerve Ablation System.
These technologies offer combination diagnostic and therapeutic functions that have the potential to reduce hospitalizations, lower surgical procedure counts, decrease healthcare costs, and improve patient outcomes through minimally invasive approaches. Beyond its current product offerings, NeuroOne is engaged in research and development for drug delivery and spinal cord stimulation programs, indicating an expanding pipeline of neurological treatment solutions. The company's focus on high-definition, high-precision electrode technology addresses significant unmet needs in neurological care, where traditional surgical approaches often involve greater invasiveness and longer recovery times.
Investors and industry observers can access the presentation through the conference webcast link, while additional conference information is available on the conference website. The timing of this presentation coincides with increasing attention on medical technologies that can improve neurological treatment outcomes while addressing healthcare cost pressures through innovative approaches to surgical care. NeuroOne's participation in the Oppenheimer conference highlights the growing importance of medical technology companies that bridge diagnostic and therapeutic functions in neurological care.
As healthcare systems worldwide seek more efficient and effective treatment pathways for complex neurological conditions, platforms like OneRF that offer combined capabilities represent a significant advancement in patient care paradigms. The company's updates at this conference will provide insight into how these technologies are progressing toward broader clinical adoption and commercial success. The presentation represents a critical juncture for NeuroOne as it seeks to demonstrate the commercial viability and clinical impact of its integrated neurological treatment platform to key stakeholders in the healthcare investment community.
